Bicara Therapeutics Inc. (BCAX)

NASDAQ: BCAX · USD

$9.74

-7.75 (-44.3%)· Recorded snapshot

Market cap	644.2M
Net income (ttm)	-185.4M
EPS (ttm)	-$3.11
Shares out	66.2M
Volume	14,620,766
Beta	-0.69

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -185.4M
EPS (ttm): -$3.11
Market cap: 644.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	نگه‌داری

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-41

P25 n/aP50 n/aP75 n/a

ROIC-27.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BCAX indicators

Market & fundamental data

Available fields

170

Groups with data

Currency

USD

Showing 170 of 170 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0002023658
Company name	Bicara Therapeutics Inc.
Country	United States
Country code	US
CUSIP number	055477103
Earnings date	2026-11-09
Earnings time	bmo
Employees	103
Employees change	48
Employees growth	87.27%
Enterprise value	$148.1M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2018
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2024-09-13
Is primary listing	Yes
Is SPAC	No
ISIN number	US0554771032
Last 10-K release date	2026-03-30
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$644.2M
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$9.74
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	BCAX
U.S. state	Massachusetts
Website	https://www.bicara.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-31.94%
FCF / EV yield	-70.89%
FCF yield	-19.69%
P/B ratio	2.46x
Price / tangible book value	1.47x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.8M
ROA	-26.14%
ROCE	-43.09%
ROE	-41.01%
ROIC	-27.83%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	2
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-400,000
Depreciation and amortization	$155,000
EBIT	$-202M
EBITDA	$-201.8M
EPS	$-3.11
FCF per share	$-2.04
Financing cash flow	$197.3M
Free cash flow	$-135.2M
Free cash flow minus SBC	$-157.4M
Income taxes	$208,000
Investing cash flow	$-402.5M
Net cash flow	$-340M
Net income	$-185.4M
Operating cash flow minus SBC	$-157M
Operating income	$-202M
Stock-based compensation	$22.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$7.11
Debt / equity	0
Long-term assets	$8.4M
Long-term liabilities	$0
Net cash (debt)	$496.1M
Net cash / market cap	72.23%
Net cash growth	14.21%
Net debt / equity	-1.06
Piotroski F-Score	1
Property, plant and equipment	$1.5M
Shareholders' equity	$468.8M
Tangible book value	$468.8M
Tangible book value per share	$7.11
Total assets	$512.2M
Total cash	$497.3M
Total debt	$1.2M
Total liabilities	$43.5M
WACC	0.43%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$503.8M
Current liabilities	$43.5M
Current ratio	11.59
Net working capital	$-35.8M
Quick ratio	11.44
Working capital	$460.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-36.51%
Dividend yield	0%
Shareholder yield	-36.51%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$22.68
1D price change	-44.31%
1M price change	-49.3%
1M total return	-49.3%
1W price change	-46.92%
1W total return	-46.92%
1Y price change	-42.71%
1Y return CAGR	-42.73%
1Y total return	-42.71%
20-day SMA	$16.99
200-day SMA	$21.29
3M price change	-64.98%
3M total return	-64.98%
50-day SMA	$20.37
50-day SMA vs 200-day SMA	50under200
52-week high	$30.99
52-week high date	2026-07-07
52-week low	$8.90
52-week low date	2026-10-28
6M price change	-56.66%
6M total return	-56.66%
All-time high	$30.99
All-time high date	2026-07-07
All-time low	$7.80
All-time low date	2025-05-23
Average true range (ATR)	$1.60
Average volume	1.5M
Beta (1Y)	0.96
Beta (2Y)	1.44
Beta (5Y)	-0.69
Change from 52-week high	-68.59%
Change from 52-week low	9.38%
Change from all-time high	-68.57%
Change from all-time low	24.87%
Change from open	-43.6%
Day's gap	-1.26%
Dollar volume	$142.3M
High price	$17.26
Low price	$8.94
Monthly RSI	35.23
Open price	$17.26
Position in 52-week range	9.56%
Premarket change	-2.12%
Premarket close	$17.48
Premarket price	$17.11
Premarket volume	10.7K
Previous close	$17.48
Price vs 150-day SMA	-57.06%
Price vs 20-day SMA	-42.67%
Price vs 200-day SMA	-54.25%
Price vs 50-day SMA	-52.18%
Relative volume	10.07
Return from IPO open	-60.46%
Return from IPO price	-42.33%
RSI	18.39
Sharpe ratio	-0.44
Sortino ratio	-0.46
Volume	14.6M
Weekly RSI	24.65
YTD price change	-42.13%
YTD total return	-42.13%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	36.9M
Float percentage	55.76%
Shares change (QoQ)	11.87%
Shares change (YoY)	36.51%
Shares held by insiders	1.84%
Shares held by institutions	67.7%
Shares outstanding	66.2M
Short % of float	27.91%
Short % of shares	15.56%
Short ratio	16.9 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	390

Deeper analysis on BCAX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BCAX report

Is a complete BCAX research report available?

No complete published report is available for Bicara Therapeutics Inc. (BCAX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Bicara Therapeutics Inc. (BCAX)

Price

Financial snapshot

Fair-value bridge

Latest news · BCAX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BCAX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on BCAX

Frequently asked questions